Report: Payers may want more biosimilar data
Payers may be more demanding about biosimilars data than regulators prove to be, a report from Decision Resources says. Apparently, payers are questioning whether the FDA's requirements will answer all of their questions about bioequivalence of branded biotech meds and other companies' copycat versions. Report
Comments